Standard

Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1. / Troitskaya, Olga; Golubitskaya, Ekaterina; Biryukov, Mikhail et al.

In: International Journal of Molecular Sciences, Vol. 21, No. 14, 5128, 20.07.2020, p. 1-14.

Research output: Contribution to journal › Article › peer-review

Harvard

Troitskaya, O, Golubitskaya, E, Biryukov, M, Varlamov, M, Gugin, P, Milakhina, E, Richter, V, Schweigert, I, Zakrevsky, D & Koval, O 2020, 'Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1', International Journal of Molecular Sciences, vol. 21, no. 14, 5128, pp. 1-14. https://doi.org/10.3390/ijms21145128

APA

Troitskaya, O., Golubitskaya, E., Biryukov, M., Varlamov, M., Gugin, P., Milakhina, E., Richter, V., Schweigert, I., Zakrevsky, D., & Koval, O. (2020). Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1. International Journal of Molecular Sciences, 21(14), 1-14. [5128]. https://doi.org/10.3390/ijms21145128

Vancouver

Troitskaya O, Golubitskaya E, Biryukov M, Varlamov M, Gugin P, Milakhina E et al. Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1. International Journal of Molecular Sciences. 2020 Jul 20;21(14):1-14. 5128. doi: 10.3390/ijms21145128

Author

Troitskaya, Olga ; Golubitskaya, Ekaterina ; Biryukov, Mikhail et al. / Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1. In: International Journal of Molecular Sciences. 2020 ; Vol. 21, No. 14. pp. 1-14.

BibTeX

@article{074d3e4209074d1882f69bec6d26ddb4,
title = "Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1",
abstract = "The application of cold atmospheric plasma (CAP) in cancer therapy could be one of the new anticancer strategies. In the current work, we used cold atmospheric plasma jet for the treatment of cultured cells and mice. We showed that CAP induced the death of MX−7 mouse rhabdomyosarcoma cells with the hallmarks of immunogenic cell death (ICD): calreticulin and heat shock protein 70 (HSP70) externalization and high-mobility group box 1 protein (HMGB1) release. The intensity of HMGB1 release after the CAP treatment correlated directly with the basal extracellular HMGB1 level. Releasing from dying cells, HMGB1 can act as a proinflammatory cytokine. Our in vivo study demonstrated that cold atmospheric plasma induces a short-term two-times increase in serum HMGB1 level only in tumor-bearing mice with no effect in healthy mice. These findings support our hypothesis that CAP-dependent HMGB1 release from dying cancer cells can change the serum HMGB1 level. At the same time, we showed a weak cytokine response to CAP irradiation in healthy mice that can characterize CAP as an immune-safety physical antitumor approach.",
keywords = "Anticancer treatment, HMGB1, Immunogenic cell death, Non-thermal plasma, Proinflammatory cytokines",
author = "Olga Troitskaya and Ekaterina Golubitskaya and Mikhail Biryukov and Mikhail Varlamov and Pavel Gugin and Elena Milakhina and Vladimir Richter and Irina Schweigert and Dmitry Zakrevsky and Olga Koval",
note = "Funding Information: Funding: The authors gratefully acknowledge financial support from Russian Science Foundation grant # 19–19–00255, Russian State funded budget project of ICBFM SB RAS # АААА-А17–117020210023–1, RFBR grant # 19–34–90134 for young scientists. The authors, E.M. and D.Z., were also partly supported by RFBR # 18–08– 00510. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jul,
day = "20",
doi = "10.3390/ijms21145128",
language = "English",
volume = "21",
pages = "1--14",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "14",

}

RIS

TY - JOUR

T1 - Non-thermal plasma application in tumor-bearing mice induces increase of serum hmgb1

AU - Troitskaya, Olga

AU - Golubitskaya, Ekaterina

AU - Biryukov, Mikhail

AU - Varlamov, Mikhail

AU - Gugin, Pavel

AU - Milakhina, Elena

AU - Richter, Vladimir

AU - Schweigert, Irina

AU - Zakrevsky, Dmitry

AU - Koval, Olga

N1 - Funding Information: Funding: The authors gratefully acknowledge financial support from Russian Science Foundation grant # 19–19–00255, Russian State funded budget project of ICBFM SB RAS # АААА-А17–117020210023–1, RFBR grant # 19–34–90134 for young scientists. The authors, E.M. and D.Z., were also partly supported by RFBR # 18–08– 00510. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/7/20

Y1 - 2020/7/20

N2 - The application of cold atmospheric plasma (CAP) in cancer therapy could be one of the new anticancer strategies. In the current work, we used cold atmospheric plasma jet for the treatment of cultured cells and mice. We showed that CAP induced the death of MX−7 mouse rhabdomyosarcoma cells with the hallmarks of immunogenic cell death (ICD): calreticulin and heat shock protein 70 (HSP70) externalization and high-mobility group box 1 protein (HMGB1) release. The intensity of HMGB1 release after the CAP treatment correlated directly with the basal extracellular HMGB1 level. Releasing from dying cells, HMGB1 can act as a proinflammatory cytokine. Our in vivo study demonstrated that cold atmospheric plasma induces a short-term two-times increase in serum HMGB1 level only in tumor-bearing mice with no effect in healthy mice. These findings support our hypothesis that CAP-dependent HMGB1 release from dying cancer cells can change the serum HMGB1 level. At the same time, we showed a weak cytokine response to CAP irradiation in healthy mice that can characterize CAP as an immune-safety physical antitumor approach.

AB - The application of cold atmospheric plasma (CAP) in cancer therapy could be one of the new anticancer strategies. In the current work, we used cold atmospheric plasma jet for the treatment of cultured cells and mice. We showed that CAP induced the death of MX−7 mouse rhabdomyosarcoma cells with the hallmarks of immunogenic cell death (ICD): calreticulin and heat shock protein 70 (HSP70) externalization and high-mobility group box 1 protein (HMGB1) release. The intensity of HMGB1 release after the CAP treatment correlated directly with the basal extracellular HMGB1 level. Releasing from dying cells, HMGB1 can act as a proinflammatory cytokine. Our in vivo study demonstrated that cold atmospheric plasma induces a short-term two-times increase in serum HMGB1 level only in tumor-bearing mice with no effect in healthy mice. These findings support our hypothesis that CAP-dependent HMGB1 release from dying cancer cells can change the serum HMGB1 level. At the same time, we showed a weak cytokine response to CAP irradiation in healthy mice that can characterize CAP as an immune-safety physical antitumor approach.

KW - Anticancer treatment

KW - HMGB1

KW - Immunogenic cell death

KW - Non-thermal plasma

KW - Proinflammatory cytokines

UR - http://www.scopus.com/inward/record.url?scp=85088162308&partnerID=8YFLogxK

UR - https://www.elibrary.ru/item.asp?id=45410715

U2 - 10.3390/ijms21145128

DO - 10.3390/ijms21145128

M3 - Article

C2 - 32698492

AN - SCOPUS:85088162308

VL - 21

SP - 1

EP - 14

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 14

M1 - 5128

ER -

ID: 24783261